

Asymmetric Catalysis. Part 149 [1]. Synthesis of New Chiral Tridentate Ligands for Enantioselective Catalysis

Henri Brunner*, Christian Zettler, and Manfred Zabel†

Institut für Anorganische Chemie, Universität Regensburg, D-93040 Regensburg, Germany

Received March 4, 2003; accepted March 4, 2003

Published online August 18, 2003 © Springer-Verlag 2003

Summary. The synthesis of new chiral tridentate ligands is reported which coordinate transition metals in a meridional way. The ligands contain a pyridine ring, an oxazoline ring, and a strongly coordinating diphenylphosphanyl group. The methionine-derived ligand forms a copper complex, which has been studied by X-ray crystallography. The new ligands were tested in models of enantioselective catalyses, such as hydrogenation of ketopantolactone, hydrosilylation of acetophenone, and transfer hydrogenation of acetophenone.

Keywords. Tridentate ligands; Chirality; Enantioselective catalysis; X-ray structure analysis.

Introduction

In the beginning of enantioselective catalysis with transition metal compounds chiral monodentate ligands played a crucial role. Soon, however, chiral bidentate ligands took over [2]. Chiral tridentate ligands, which may coordinate the metal atom of a catalyst in a meridional or a facial way, have not been used extensively in enantioselective catalysis. In the present paper we describe series of chiral tridentate ligands which contain a pyridine ring, an oxazoline ring, rendered chiral by way of its aminoalcohol constituent, and a strongly coordinating diphenylphosphanyl group or a methylsulfanyl group [3]. The new ligands were tested in different models of enantioselective catalysis including hydrogenations, for which the diphenylphosphanyl group proved essential to activate molecular hydrogen [3].

* Corresponding author. E-mail: henri.brunner@chemie.uni-regensburg.de


† X-ray structure analyses

Results and Discussion

Synthesis of Pyridine-Oxazoline Ligands with a $\text{CH}_2\text{P}(\text{O})\text{Ph}_2$ Group as a Pyridine Substituent


To synthesize pyridine derivatives with different substituents in 2,6-position, one of the two hydroxy groups of commercially available 2,6-(dihydroxymethyl)pyridine (**1**) had to be protected as a silyl ether. This was achieved by reaction with NaH followed by addition of $\text{Ph}_2{}^t\text{BuSiCl}$ to give the monosilyl ether **2** in 77% yield [4]. The free hydroxy group in **2** was transformed into the tosylate leaving group in **3** with TsCl [5]. In the reaction with LiPPh_2 tosylate was replaced by diphenylphosphide. Subsequent oxidation with air gave the phosphanoyl derivative **4**. Deprotection of the silyl ether group in **5** was accomplished with Bu_4NF [6]. The free hydroxy group in **5** was oxidised to the aldehyde group in **6** by a *Swern* oxidation [7, 8]. Aldehyde **6** was converted into oxime **7** with hydroxylamine [9]. Addition of 1,1'-carbonyldiimidazol to **7** afforded the nitrile **8** [10], which was transformed into the carbomethoxyimide **9** with NaOMe [11]. The precursors **1–9** are shown in Scheme 1.

The oxazoline rings in compounds **10–13** were built up in the reaction of **9** with the 2-aminoalcohols (*R*)-2-aminobutanol, (*S*)-valinol, (*S*)-phenylalaninol, and (*S*)-phenylglycinol (Scheme 2) [12]. Unfortunately, the phosphanoyl groups in these compounds could not be reduced to the phosphanyl functionality with HSiCl_3 , which normally is used for such reductions [13, 14]. In these reactions diphenylphosphinic acid was cleaved off, characterised by ^{31}P NMR and X-ray crystallography [3].



	<i>R</i>	<i>R'</i>
1	CH_2OH	CH_2OH
2	$\text{CH}_2\text{OSi}^t\text{BuPh}_2$	CH_2OH
3	$\text{CH}_2\text{OSi}^t\text{BuPh}_2$	CH_2OTos
4	$\text{CH}_2\text{OSi}^t\text{BuPh}_2$	$\text{CH}_2\text{P}(\text{O})\text{Ph}_2$
5	CH_2OH	$\text{CH}_2\text{P}(\text{O})\text{Ph}_2$
6	CHO	$\text{CH}_2\text{P}(\text{O})\text{Ph}_2$
7	CHNOH	$\text{CH}_2\text{P}(\text{O})\text{Ph}_2$
8	CN	$\text{CH}_2\text{P}(\text{O})\text{Ph}_2$
9	$\text{C}(\text{NH})\text{OCH}_3$	$\text{CH}_2\text{P}(\text{O})\text{Ph}_2$
14	$\text{CH}_2\text{OSi}^t\text{BuPh}_2$	$\text{CH}_2\text{PPH}_2\text{BH}_3$
15	CH_2OH	$\text{CH}_2\text{PPH}_2\text{BH}_3$
16	CHO	$\text{CH}_2\text{PPH}_2\text{BH}_3$
17	CHNOH	$\text{CH}_2\text{PPH}_2\text{BH}_3$
18	CN	$\text{CH}_2\text{PPH}_2\text{BH}_3$
19	$\text{C}(\text{NH})\text{OCH}_3$	$\text{CH}_2\text{PPH}_2\text{BH}_3$

Scheme 1



Scheme 2

Synthesis of Pyridine-Oxazoline Ligands with a CH_2PPh_2 Group as a Pyridine Substituent

As the reduction of the phosphanoyl group in compounds **10–13** failed, oxidation of the phosphorus atom in the diphenylphosphanyl moiety must be prevented. A suitable protecting group for phosphorus in phosphanes is BH_3 . By addition of $\text{BH}_3 \cdot \text{THF}$ after the reaction of tosylate **3** with LiPPh_2 , the phosphorus-protected product **14** was formed (Scheme 1) [15, 16]. A crystal structure proved the coordination of the BH_3 group to the phosphorus atom (Fig. 1). The following steps implying the intermediates **14–19** (Scheme 1) and the oxazoline derivatives **20–23** (Scheme 2) are analogous to those described above for the synthesis of **4–9** and **10–13**. The protecting BH_3 groups in **20–23** were removed by stirring with Et_2NH [17] yielding the target ligands **24–27** (Scheme 3), air-sensitive compounds even as solids.

The results of the catalytic reactions with ligands **24–27** did not meet the expectations (see below). An explanation could be the dissociation of the oxazoline nitrogen from the metal atom. Thus, the chiral centre would be too far away from the reaction centre to appreciably influence the formation of the product configuration. To avoid this dissociation, we tried to synthesize a pyridine-oxazoline ligand having the strongly coordinating diphenylphosphanyl group as a substituent directly on the oxazoline ring.

Synthesis of a Pyridine-Oxazoline Ligand with a CH_2PPh_2 Group as an Oxazoline Substituent

The synthesis of target ligands of type **32** started from the methyl ester of (*S*)-serine. Its derivatisation by introducing a *Boc* group at the nitrogen atom and by forming an oxazolidine ring on reaction with 2,2-dimethoxypropane as well as by






Fig. 1. View of **14** (H atoms omitted for clarity); selected bond lengths (Å) and angles (°): P1–C7 1.8303(18), P1–B1 1.914(2), Si1–O1 1.6482(12); C7–P1–C24 104.40(7), C7–P1–B1 112.25(9)




Scheme 3

reduction of the ester group to a primary alcoholic group and by transformation into the tosylate **28** has been reported [18]. Reaction of tosylate **28** with LiPPh_2 followed by addition of $\text{BH}_3 \cdot \text{THF}$ and HCl cleavage of the oxazolidine ring in **29** has been mentioned in literature [19]. However, **29** and **30** (Scheme 4) have not been characterised. Therefore, they are included in the Experimental Part. The ring cleavage in **29** was achieved by stirring with MeOH saturated with HCl for 5 min [20]. Longer reaction times led to loss of the borane protecting group. The 2-aminoalcohol **30** was converted to the oxazoline **31** with pyridine-2-carbomethoxyimide. The target ligand **32** (Scheme 4) was obtained by deprotection of the phosphorus with Et_2NH as described above.



Scheme 4



Scheme 5

Synthesis of the CuCl₂ Complex of a Pyridine-Oxazoline Ligand with a CH₂CH₂SMe Substituent

The tridentate ligands **24–27** and **32** should coordinate to a metal centre in a meridional way. With the carbon chain of the oxazoline substituent being longer, the ligand would have the possibility to lift its “arm” and coordinate facially to a metal centre. We tested this idea with ligand **33** synthesised starting from *L*-methionine *via* the aminoalcohol (*S*)-methioninol [12]. In methanol CuCl₂ and **33** gave crystals of the complex **34** (Scheme 5) suitable for X-ray analysis (Fig. 2). The coordination geometry at the copper atom is square pyramidal. The two chlorine atoms remain bonded. Ligand **33** coordinates meridionally to the copper atom.

Catalytic Hydrogenation of Ketopantolactone

In the enantioselective hydrogenation of ketopantolactone the precatalyst [Rh(*cod*)Cl]₂ was dissolved in 7 cm³ of toluene or *THF*. The chiral ligand was dissolved in 1 cm³ of the solvent (1.1-fold excess of ligand) and added. The colour changed from yellow to dark violet indicating complexation. After stirring the solution at room temperature for 30 min the reaction was started by addition of 200 equivalents of ketopantolactone. The hydrogenation was carried out at a hydrogen pressure of 50 bar and 50°C under careful exclusion of air [21, 22].





Fig. 2. View of **34** (H atoms omitted for clarity); selected bond lengths (Å) and angles (°): Cu1–S1 2.4085(7), Cu1–Cl1 2.4353(6), Cu1–N2 1.9700(17); N2–Cu1–S1 90.76(5), N1–Cu1–Cl2 94.01(5), Cl1–Cu1–Cl2 102.67(2)

Table 1. Enantioselective hydrogenation of ketopantolactone with *in situ* catalysts [Rh(*cod*)Cl]₂/**24**–**27** and **32**^a




Procatalyst	Ligand	Solvent	Yield % ^b	<i>ee</i> %	Config.
[Rh(<i>cod</i>)Cl] ₂	24	<i>THF</i>	18.2	4.1	(<i>S</i>)
[Rh(<i>cod</i>)Cl] ₂	25	<i>THF</i>	3.1	<1.0	(<i>R</i>)
[Rh(<i>cod</i>)Cl] ₂	26	<i>THF</i>	14.1	1.2	(<i>R</i>)
[Rh(<i>cod</i>)Cl] ₂	27	<i>THF</i>	24.8	1.2	(<i>R</i>)
[Rh(<i>cod</i>)Cl] ₂	32	<i>THF</i>	40.4	1.8	(<i>S</i>)
[Rh(<i>cod</i>)Cl] ₂	32	toluene	36.5	17.1	(<i>S</i>)

^a Conditions: Rh:ligand:substrate = 1:1.1:200, *p* = 50 bar, *T* = 50°C, *t* = 40 h; work-up and enantiomer analysis see Ref. [22]; ^b yield of pantolactone

After a reaction time of 40 h the colour of the solution was still dark violet. The colour changed to yellow on contact with air. Table 1 shows that the hydrogenation yields are in the lower and middle area. The *in situ* catalyst [Rh(*cod*)Cl]₂/**32** afforded 36.3% yield and 17% *ee*.

Catalytic Hydrosilylation of Acetophenone

To the procatalyst [Rh(*cod*)Cl]₂ a 1.1-fold excess of a solution of the ligand in CH₂Cl₂ was added. The colour changed to dark violet. The solution was stirred at

Table 2. Enantioselective hydrosilylation of acetophenone with *in situ* catalysts $[\text{Rh}(\text{cod})\text{Cl}]_2$ /**24–27**, **32**, and **33**^a


Procatalyst	Ligand	HS % ^b	EE % ^c	Yield % ^d	ee %	Config.
$[\text{Rh}(\text{cod})\text{Cl}]_2$	24	86.0	9.0	78.3	<1.0	(<i>R</i>)
$[\text{Rh}(\text{cod})\text{Cl}]_2$	25	86.9	6.4	81.4	<1.0	(<i>S</i>)
$[\text{Rh}(\text{cod})\text{Cl}]_2$	26	85.2	10.2	76.5	<1.0	(<i>S</i>)
$[\text{Rh}(\text{cod})\text{Cl}]_2$	27	84.6	14.7	72.2	6.9	(<i>R</i>)
$[\text{Rh}(\text{cod})\text{Cl}]_2$	32	83.5	41.2	49.3	8.8	(<i>S</i>)
$[\text{Rh}(\text{cod})\text{Cl}]_2$	33	76	47.9	39.6	<1.0	(<i>R</i>)

^a Conditions: Rh:ligand:substrate:diphenylsilane = 1:1.1:400:400, $T = 0^\circ\text{C} \rightarrow \text{rt}$, $t = 24 \text{ h}$; work-up and enantiomer analysis see Ref. [24]; ^b HS = hydrosilylation; ^c EE = enoether; ^d yield of 1-phenylethanol

room temperature for 30 min. Then the solvent was removed. The reaction was started by addition of acetophenone and diphenylsilane [23, 24]. Yields were good (Table 2), however, the enantiomeric excess was very low in all runs, except for ligand **27** (6.9% *ee*) and ligand **32** (8.8% *ee*).

Catalytic Hydrogenation of Acetophenone

After adding a 1.1-fold excess of ligand to the procatalyst $[\text{RuCl}_2(\text{PPh}_3)_3]$ the 2-propanol solution was stirred at room temperature for 1 h. Then the substrate

Table 3. Enantioselective transfer hydrogenation of acetophenone with *in situ* catalysts $[\text{RuCl}_2(\text{PPh}_3)_3]$ /**24–27**, **32**, and **33**^a

Procatalyst	Ligand	Time h	Yield % ^b	ee %	Config.
$[\text{RuCl}_2(\text{PPh}_3)_3]$	24	15	15.9	10.8	(<i>R</i>)
$[\text{RuCl}_2(\text{PPh}_3)_3]$	25	15	4.3	9.0	(<i>S</i>)
$[\text{RuCl}_2(\text{PPh}_3)_3]$	26	15	20.6	6.7	(<i>S</i>)
$[\text{RuCl}_2(\text{PPh}_3)_3]$	27	15	15.2	1.3	(<i>S</i>)
$[\text{RuCl}_2(\text{PPh}_3)_3]$	32	15	1.8	34.2	(<i>S</i>)
$[\text{RuCl}_2(\text{PPh}_3)_3]$	32	72	2.8	38.1	(<i>S</i>)
$[\text{RuCl}_2(\text{PPh}_3)_3]$	33	15	1.9	15.1	(<i>R</i>)

^a Conditions: Ru:ligand:substrate: KO^tBu = 1:1.1:200:1, solvent 2-propanol, $T = 28^\circ\text{C}$; work-up and enantiomer analysis see Ref. [26]; ^b yield of 1-phenylethanol

acetophenone (200-fold excess) and the base potassium-*tert*-butanolate were added [25, 26]. The results are shown in Table 3. The highest enantiomeric excess was 38% *ee* obtained with ligand **32**.

Experimental

Chromatography: Silica gel 60 (Merck). NMR spectra: Bruker AC 250, Bruker ARX 400 spectrometer. Mass spectra: Finnigan Mat 95 (FD and FAB), Finnigan 311A (EI), Thermoquest TSQ 7000 (ESI). The most intense peak is specified. Optical rotations: Perkin Elmer polarimeter 241.

(*R*)-(-)-2-Aminobutanol was commercially available. (*S*)-(+)-Valinol, (*S*)-(-)-phenylalaninol, (*S*)-(-)-phenylglycinol, and (*S*)-(+)-methioninol were obtained by reduction of the corresponding aminoacids [27]. (*S*)-*N*-Boc-2,2-dimethyl-4-tosyloxymethylloxazolidine **28** was synthesised as described starting from (*S*)-(+)-serine [18].

6-[(*tert*-Butyldiphenylsilyl)oxymethyl]-2-(hydroxymethyl)pyridine (**2**, C₂₃H₂₇NO₂Si)

To a suspension of 1.11 g of NaH (46.0 mmol) in 40 cm³ of *THF* 5.85 g of 2,6-dihydroxymethylpyridine (**1**, 42.0 mmol), dissolved in 250 cm³ of *THF*, were added at room temperature within 2 h under an atmosphere of dry N₂. A solution of 10.8 cm³ of *tert*-butyldiphenylchlorosilane (42 mmol) in 5 cm³ of *THF* was added dropwise with stirring at room temperature. The brown suspension was poured into a mixture of 165 cm³ of diethyl ether and 22 cm³ of a 10% Na₂CO₃ solution. The organic layer was dried (Na₂SO₄) and evaporated. The resulting pale yellow oil was chromatographed on a SiO₂ column (35 × 4 cm) with petroleum ether:ethyl acetate = 2:1. After the first fraction, consisting of the doubly silylated compound, the main fraction was **2** (colourless solid). The unprotected dialcohol **1** remained on the column. Yield 12.27 g (77%); mp 133°C; PI DCI MS: *m/z* = 378 (M, 100); ¹H NMR (250 MHz, CDCl₃, *TMS*): δ = 7.72 (m, 5H, Ph, Py), 7.59 (d, *J* = 7.4 Hz, H³-Py), 7.41 (m, 6H, Ph), 7.09 (d, *J* = 7.6 Hz, H⁵-Py), 4.88 (s, CH₂OSi), 4.70 (d, *J* = 4.8 Hz, CH₂OH), 3.71 (t, *J* = 4.8 Hz, CH₂OH), 1.14 (s, C(CH₃)₃).

6-[(*tert*-Butyldiphenylsilyl)oxymethyl]-2-(tosyloxymethyl)pyridine (**3**, C₃₀H₃₃NO₄Si)

Powdered KOH (1.72 g, 30.7 mmol) was added to a solution of 7.18 g of **2** (19.0 mmol) in 30 cm³ of *THF*. To this suspension a solution of 4.20 g of *TosCl* (22.0 mmol) in 15 cm³ of *THF* was added dropwise at 0°C. The suspension was stirred for 5 h at 0°C and 12 h at room temperature. After filtration the residue was washed with a small amount of *THF* and the combined solutions were evaporated. The resulting solid was chromatographed (SiO₂, 40 × 6 cm) with petroleum ether:ethyl acetate = 7:1 to give **3** as a colourless solid. Yield 10.10 g (89%); mp 63–64°C; PI FD MS (CH₂Cl₂): *m/z* = 474 (M–C(CH₃)₃, 100); ¹H NMR (250 MHz, CDCl₃, *TMS*): δ = 7.71 (m, 8H, Ph, Py), 7.34 (m, 9H, Ph, Py), 5.05 (s, CH₂OTos), 4.77 (s, CH₂OSi), 2.41 (s, CH₃), 1.12 (s, C(CH₃)₃).

2-[(*tert*-Butyldiphenylsilyl)oxymethyl]-6-[(diphenylphosphanoyl)methyl]pyridine (**4**, C₃₅H₃₆NO₂PSi)

Under N₂ a solution of 3.50 g of **3** (6.58 mmol) in 50 cm³ of *THF* was cooled to –50°C. An equimolar solution of LiPPh₂ (1 molar) in *THF* was added dropwise. Each drop was immediately decolourized. The resulting pale yellow solution was stirred for 1 h at –50°C and for 2 h at room temperature. Then the solution was stirred for 3 h on air. After removal of the solvent the residue was chromatographed (SiO₂, 35 × 4 cm) with CH₂Cl₂:methanol = 50:1 to afford **4** as a colourless solid. Yield 2.25 g (61%); PI FD MS (CH₂Cl₂): *m/z* = 562 (M, 4), 504 (M–C(CH₃)₃, 100); ¹H NMR (250 MHz, CDCl₃, *TMS*):

$\delta = 7.66$ (m, 9H, Ph, Py), 7.40 (m, 14H, Ph, Py), 4.66 (s, CH_2OSi), 3.84 (d, $J = 14.2$ Hz, CH_2P), 1.10 (s, $\text{C}(\text{CH}_3)_3$) ppm; $^{31}\text{P}\{^1\text{H}\}$ NMR (CDCl_3 , H_3PO_4 ext.): $\delta = 30.58$ (s, POPh_2) ppm.

6-(Diphenylphosphanoyl- κ P-methyl)-2-(hydroxymethyl)pyridine (5, $\text{C}_{19}\text{H}_{18}\text{NO}_2\text{P}$)

$\text{Bu}_4\text{NF} \cdot 3\text{H}_2\text{O}$ (1.61 g, 5.11 mmol) was added to a solution of 2.61 g of **4** (4.65 mmol) in 50 cm^3 of *THF*. The colour of the solution turned yellow. After stirring for 2 h at room temperature the solvent was evaporated and the residue was chromatographed (SiO_2 , 25×3 cm) with CH_2Cl_2 :methanol = 20:1 to give the colourless solid **5**. Yield 1.29 g (86%); mp 126°C ; PI EI MS: $m/z = 323$ (M, 9), 201 (Ph_2PO , 73), 199 (M-Ph- CH_2OH , 100); ^1H NMR (400 MHz, CDCl_3 , *TMS*): $\delta = 7.55$ (ddd, $J = 7.7$, 7.7, 0.4 Hz, H^4 -Py), 7.52 (m, 3H, Ph), 7.45 (m, 7H, Ph), 7.66 (ddd, $J = 7.7$, 1.8, 0.9 Hz, 1H, $\text{H}^{3/5}$ -Py), 7.73 (ddd, $J = 7.7$, 1.8, 0.9 Hz, 1H, $\text{H}^{3/5}$ -Py), 4.54 (s, CH_2OH), 3.93 (d, $J = 14.0$ Hz, CH_2P), 3.60 (s, CH_2OH) ppm; $^{31}\text{P}\{^1\text{H}\}$ NMR (CDCl_3 , H_3PO_4 ext.): $\delta = 30.60$ (s, POPh_2) ppm.

6-[(Diphenylphosphanoyl)methyl]pyridine-2-carbaldehyde (6, $\text{C}_{19}\text{H}_{16}\text{NO}_2\text{P}$)

Under N_2 a solution of 310 mm^3 of oxalyl chloride (3.61 mmol) in 8 cm^3 of CH_2Cl_2 was cooled to -80°C . A solution of 530 mm^3 of *DMSO* (7.46 mmol) in 2 cm^3 of CH_2Cl_2 was added dropwise such that gas evolution was not too vigorous. After 5 min a solution of 1.0 g of **5** (3.11 mmol) in 8 cm^3 of CH_2Cl_2 was added dropwise and stirred for 15 min at -80°C . After adding 2.20 cm^3 of NEt_3 (15.87 mmol) a brown precipitate formed immediately. The suspension was stirred while warming to room temperature. H_2O (16 cm^3) was added which dissolved the precipitate. The yellow-orange organic layer was washed twice with H_2O , dried (Na_2SO_4), and the solvent was evaporated. The residue was chromatographed (SiO_2 , 25×3 cm) with dichloromethane:methanol = 30:1. The resulting **6** was obtained as a yellow solid. Yield 0.96 g (96%); mp 105°C ; PI EI MS: $m/z = 321$ (M, 5), 201 (POPh_2 , 100); ^1H NMR (400 MHz, CDCl_3 , *TMS*): $\delta = 9.83$ (d, $J = 0.6$ Hz, CHO), 7.77 (m, 6H, Ph, Py), 7.58 (m, 7H, Ph, Py), 4.02 (d, $J = 13.9$ Hz, CH_2P) ppm; $^{31}\text{P}\{^1\text{H}\}$ NMR (CDCl_3 , H_3PO_4 ext.): $\delta = 30.32$ (s, POPh_2) ppm.

6-[(Diphenylphosphanoyl)methyl]pyridine-2-carbaldoxime (7, $\text{C}_{19}\text{H}_{17}\text{N}_2\text{O}_2\text{P}$)

$\text{H}_2\text{NOH} \cdot \text{HCl}$ (2.02 g, 29.1 mmol) was dissolved in 18 cm^3 of a 10% Na_2CO_3 solution and stirred until gas evolution stopped. This solution was added to a solution of 6.00 g of **6** (18.7 mmol) in 40 cm^3 of *MeOH* and stirred for 24 h at room temperature. After a few min a colourless precipitate formed. The suspension was concentrated and the precipitate was filtered off and washed with petroleum ether. The filtrate was evaporated and the residue was chromatographed (SiO_2 , 25×3 cm) with CH_2Cl_2 :methanol = 20:1. Compound **7** was obtained as a colourless solid. Yield 5.10 g (81%); mp $217\text{--}218^\circ\text{C}$; PI EI MS: $m/z = 336$ (M, 4), 318 (M- H_2O , 6), 201 (POPh_2 , 100); ^1H NMR (400 MHz, *DMSO*- d_6 , *TMS*): $\delta = 11.63$ (s, HCNOH), 7.82 (m, 5H, Ph, HCNOH), 7.67 (dd, $J = 7.7$, 7.7 Hz, H^4 -Py), 7.53 (m, 7H, Ph, H^5 -Py), 7.25 (ddd, $J = 7.7$, 1.9, 1.1 Hz, H^3 -Py), 4.10 (d, $J = 11.9$ Hz, CH_2P) ppm; $^{31}\text{P}\{^1\text{H}\}$ NMR (*DMSO*- d_6 , H_3PO_4 ext.): $\delta = 28.92$ (s, 1P, POPh_2) ppm.

6-[(Diphenylphosphanoyl)methyl]pyridine-2-carbonitrile (8, $\text{C}_{19}\text{H}_{15}\text{N}_2\text{O}_2\text{P}$)

To a solution of 2.0 g of **7** (6.2 mmol) in 70 cm^3 of dried *DMSO* 1.17 g of 1,1'-carbonyldiimidazol (7.2 mmol) were added. After stirring for 2 h at room temperature the solvent was evaporated. The residue was chromatographed (SiO_2 , 25×3 cm) with CH_2Cl_2 :methanol = 30:1. Compound **8** was obtained as a colourless solid. Yield 1.82 (92%); mp 147°C ; PI EI MS: $m/z = 318$ (M, 15), 201 (POPh_2 , 100); $^1\text{H}\{^{31}\text{P}\}$ NMR (400 MHz, CDCl_3 , *TMS*): $\delta = 7.78$ (dd, $J = 8.0$, 1.1 Hz, H^3 -Py), 7.75 (m, 4H, Ph), 7.71 (dd, $J = 8.0$, 8.0 Hz, H^4 -Py), 7.49 (m, 7H, Ph, H^5 -Py), 3.96 (s, CH_2P) ppm; $^{31}\text{P}\{^1\text{H}\}$ NMR (CDCl_3 , H_3PO_4 ext.): $\delta = 30.39$ (s, POPh_2) ppm.

6-[(Diphenylphosphanoyl)methyl]pyridine-2-carbomethoxyimide (**9**, C₂₀H₁₉N₂O₂P)

A solution of **8** (1.35 g, 3.9 mmol) in 80 cm³ of MeOH was reacted with a solution of 0.096 g of sodium (4.2 mmol) in 10 cm³ of MeOH under N₂. After stirring for 48 h at room temperature 280 mm³ of glacial acetic acid (4.9 mmol) were added. The solvent was removed and the residue was dissolved in CH₂Cl₂. The solution was extracted twice with H₂O, the organic layer was dried over Na₂SO₄, and the solvent was evaporated to give **9** as a colourless solid. Yield 1.28 (94%); mp 176–177°C; PI EI MS: *m/z* = 350 (M, 2), 319 (M–OCH₃, 12), 201 (POPh₂, 100); ¹H NMR (250 MHz, CDCl₃, TMS): δ = 8.62 (bs, NH), 7.79 (m, 4H, Ph), 7.68 (ddd, *J* = 7.7, 7.7, 0.5 Hz, H⁴-Py), 7.61 (ddd, *J* = 7.7, 1.4, 1.3 Hz, H⁵-Py), 7.50 (m, 7H, Ph, H³-Py), 3.96 (d, *J* = 14.0 Hz, CH₂P), 3.93 (s, OCH₃) ppm; ³¹P{¹H} NMR (CDCl₃, H₃PO₄ ext.): δ = 30.57 (s, POPh₂) ppm.

General Procedure for the Synthesis of Compounds **10**–**13** from **9** with 2-Aminoalcohols

9 was dissolved in ca. 30 cm³ of chlorobenzene at 80°C. The corresponding 2-aminoalcohol (2.93 mmol) and one drop of conc. HCl as catalyst were added. N₂ was bubbled through the solution for 20 h to remove the compounds with low boiling points like MeOH or NH₃ displacing the equilibrium to the product side. After evaporating the solvent the residue was chromatographed (SiO₂, 20×3 cm) with CH₂Cl₂:methanol = 30:1.

(*R*)-2-[(Diphenylphosphanoyl)methyl]-6-(4-ethyl-4,5-dihydrooxazol-2-yl)pyridine (**10**, C₂₃H₂₃N₂O₂P)

From (*R*)-(–)-2-aminobutanol as aminoalcohol. Colourless resin. Yield 1.05 g (94%); PI EI MS: *m/z* = 390 (M, 14), 361 (M–C₂H₅, 8), 201 (Ph₂PO, 100); ¹H{³¹P} NMR (400 MHz, CDCl₃, TMS): δ = 7.85 (ddd, *J* = 7.6, 1.3, 1.4 Hz, H³-Py), 7.77 (m, 4H, Ph), 7.71 (ddd, *J* = 7.8, 1.3, 1.7 Hz, H⁵-Py), 7.65 (dd, *J* = 7.6, 7.8 Hz, H⁴-Py), 7.44 (m, 6H, Ph), 4.53 (dd, *J* = 8.1, 9.6 Hz, OCH^AH^BCHN), 4.28 (m, OCH^AH^BCHN), 4.11 (dd, *J* = 8.1, 8.1 Hz, OCH^AH^BCHN), 4.06 (d, *J* = 14.2 Hz, CH^AH^BPO), 4.05 (d, *J* = 14.2 Hz, CH^AH^BPO), 1.79 (m, CH^AH^BCH₃), 1.63 (m, CH^AH^BCH₃), 1.00 (t, *J* = 7.2 Hz, CH^AH^BCH₃) ppm; ³¹P{¹H} NMR (CDCl₃, H₃PO₄ ext.): δ = 30.50 (s, POPh₂); IR (KBr): $\bar{\nu}$ = 1200 (s) cm^{–1}; [α]_D = +37.0° cm³ g^{–1} dm^{–1} (*c* = 1.0, CH₂Cl₂).

(*S*)-2-[(Diphenylphosphanoyl)methyl]-6-(4-isopropyl-4,5-dihydrooxazol-2-yl)pyridine (**11**, C₂₄H₂₅N₂O₂P)

From (*S*)-(+)-valinol as aminoalcohol. Colourless resin. Yield 0.80 g (69%); PI EI MS: *m/z* = 404 (M, 29), 361 (M–C₃H₇, 63), 201 (Ph₂PO, 100); ¹H{³¹P} NMR (400 MHz, CDCl₃, TMS): δ = 7.86 (ddd, *J* = 7.5, 1.5, 1.5 Hz, H³-Py), 7.77 (m, 4H, Ph), 7.69 (ddd, *J* = 7.8, 1.5, 1.7 Hz, H⁵-Py), 7.64 (dd, *J* = 7.5, 7.8 Hz, H⁴-Py), 7.44 (m, 6H, Ph), 4.45 (dd, *J* = 8.7, 7.5 Hz, OCH^AH^BCHN), 4.17 (m, OCH^AH^BCHN), 4.07 (d, *J* = 14.7 Hz, CH^AH^BP), 4.04 (d, *J* = 14.7 Hz, CH^AH^BP), 1.90 (m, CHCH₃CH₃), 1.02 (d, *J* = 6.8 Hz, CHCH₃CH₃), 0.93 (d, *J* = 6.7 Hz, CHCH₃CH₃) ppm; ³¹P{¹H} NMR (CDCl₃, H₃PO₄ ext.): δ = 30.51 (s, POPh₂) ppm; IR (KBr): $\bar{\nu}$ = 1200 (s) cm^{–1}; [α]_D = –40.0° cm³ g^{–1} dm^{–1} (*c* = 1.0, CH₂Cl₂).

(*S*)-2-[(Diphenylphosphanoyl)methyl]-6-(4-benzyl-4,5-dihydrooxazol-2-yl)pyridine (**12**, C₂₈H₂₅N₂O₂P)

From (*S*)-(–)-phenylalaninol as aminoalcohol. Colourless solid. Yield 0.78 g (61%); mp 148–149°C; PI DCI MS: *m/z* = 470 (M + NH₄, 27), 453 (M, 100); ¹H{³¹P} NMR (400 MHz, CDCl₃, TMS): δ = 7.85 (dd, *J* = 7.4, 1.3 Hz, H³-Py), 7.77 (m, 4H, Ph), 7.72 (dd, *J* = 7.8, 1.3 Hz, H⁵-Py), 7.66 (dd, *J* = 7.5, 7.8 Hz, H⁴-Py), 7.42 (m, 6H, Ph), 7.28 (m, 5H, Ph), 4.62 (m, OCH^AH^BCHN), 4.40 (dd, *J* = 8.6,

9.4 Hz, $\text{OCH}^{\text{A}}\text{H}^{\text{B}}\text{CHN}$), 4.19 (dd, $J = 8.6, 7.6$ Hz, $\text{OCH}^{\text{A}}\text{H}^{\text{B}}\text{CHN}$), 4.08 (d, $J = 14.9$ Hz, $\text{CH}^{\text{A}}\text{H}^{\text{B}}\text{P}$), 4.03 (d, $J = 14.9$ Hz, $\text{CH}^{\text{A}}\text{H}^{\text{B}}\text{P}$), 3.27 (dd, $J = 13.7, 5.0$ Hz, $\text{CH}^{\text{A}}\text{H}^{\text{B}}\text{Ph}$), 2.75 (dd, $J = 13.7, 8.9$ Hz, $\text{CH}^{\text{A}}\text{H}^{\text{B}}\text{Ph}$) ppm; $^{31}\text{P}\{^1\text{H}\}$ NMR (CDCl_3 , H_3PO_4 ext.): $\delta = 30.48$ (s, POPh_2) ppm; IR (KBr): $\bar{\nu} = 1190$ (s) cm^{-1} ; $[\alpha]_{\text{D}} = -20.0^\circ \text{ cm}^3 \text{ g}^{-1} \text{ dm}^{-1}$ ($c = 1.0$, CH_2Cl_2).

(*S*)-2-[(*Diphenylphosphanoyl*)methyl]-6-(4-phenyl-4,5-dihydrooxazol-2-yl)pyridine
(**13**, $\text{C}_{27}\text{H}_{23}\text{N}_2\text{O}_2\text{P}$)

From (*S*)-(-)-phenylglycinol as 2-aminoalcohol. Colourless resin. Yield 0.50 (40%); LT PI LSI MS: $m/z = 439$ (M, 100); $^1\text{H}\{^{31}\text{P}\}$ NMR (400 MHz, CDCl_3 , *TMS*): $\delta = 7.94$ (dd, $J = 7.3, 1.5$ Hz, $\text{H}^3\text{-Py}$), 7.78 (m, 4H, Ph), 7.72 (dd, $J = 7.8, 1.5$ Hz, $\text{H}^5\text{-Py}$), 7.68 (dd, $J = 7.3, 7.8$ Hz, $\text{H}^4\text{-Py}$), 7.39 (m, 11H, Ph), 5.41 (dd, $J = 10.1, 8.3$ Hz, $\text{OCH}^{\text{A}}\text{H}^{\text{B}}\text{CHN}$), 4.84 (dd, $J = 10.1, 8.5$ Hz, $\text{OCH}^{\text{A}}\text{H}^{\text{B}}\text{CHN}$), 4.34 (dd, $J = 8.3, 8.5$ Hz, $\text{OCH}^{\text{A}}\text{H}^{\text{B}}\text{CHN}$), 4.10 (d, $J = 14.7$ Hz, $\text{CH}^{\text{A}}\text{H}^{\text{B}}\text{P}$), 4.04 (d, $J = 14.7$ Hz, $\text{CH}^{\text{A}}\text{H}^{\text{B}}\text{P}$) ppm; $^{31}\text{P}\{^1\text{H}\}$ NMR (CDCl_3 , H_3PO_4 ext.): $\delta = 30.56$ (s, POPh_2) ppm; IR (KBr): $\bar{\nu} = 1190$ (s) cm^{-1} ; $[\alpha]_{\text{D}} = +54.0^\circ \text{ cm}^3 \text{ g}^{-1} \text{ dm}^{-1}$ ($c = 1.0$, CH_2Cl_2).

Trihydroborane[2-[(*tert*-butyldiphenylsilyl)oxymethyl]-6-(*diphenylphosphanyl*- κ *P*-methyl)pyridine] (**14**, $\text{C}_{35}\text{H}_{39}\text{BNOPSi}$)

After LiPPh_2 had been added, as described in the synthesis of **4**, the solution was stirred for 3 h under exclusion of air. The protecting group was introduced by adding $\text{BH}_3\cdot\text{THF}$ (1 molar) in 6.58 cm^3 of *THF* to the solution and stirring for 3 h at room temperature. After removal of the solvent the residue was chromatographed (SiO_2 , $35 \times 4 \text{ cm}$) with petroleum ether:ethyl acetate = 6:1. The main fraction was **14** forming a colourless solid. Yield 2.80 g (76%); mp $87\text{--}89^\circ\text{C}$; PI FD MS (CH_2Cl_2): $m/z = 559$ (M, 8), 546 (M-BH₃, 6), 502 (M-C(CH₃)₃, 100); ^1H NMR (400 MHz, CD_3OD , *TMS*): $\delta = 7.63$ (m, 9H, Ph, Py), 7.41 (m, 13H, Ph, Py), 7.06 (m, 1H, Py), 4.55 (s, CH_2OSi), 3.81 (d, $J = 12.0$ Hz, CH_2P), 1.09 (s, $\text{C}(\text{CH}_3)_3$) ppm; $^{31}\text{P}\{^1\text{H}\}$ NMR (CD_3OD , H_3PO_4 ext.): $\delta = 19.75$ (d, $J = 50.4$ Hz, PPh_2BH_3) ppm; IR (KBr): $\bar{\nu} = 2400$ (s) cm^{-1} .

Trihydroborane[6-(*diphenylphosphanyl*- κ *P*-methyl)-2-(hydroxymethyl)pyridine]
(**15**, $\text{C}_{19}\text{H}_{21}\text{BNOP}$)

Procedure as described for **14**, including molar amounts of reactants and quantities of solvent as in the synthesis of **5**. The eluent in the chromatography was petroleum ether:ethyl acetate = 1:2 to give **15** as a colourless solid. Yield 1.33 g (89%); mp $125\text{--}126^\circ\text{C}$; PI FD MS (CH_2Cl_2): $m/z = 321$ (M, 100), 307 (M-BH₃, 10); ^1H NMR (400 MHz, CDCl_3 , *TMS*): $\delta = 7.70$ (m, 4H, Ph), 7.54 (ddd, $J = 7.7, 7.7, 0.6$ Hz, $\text{H}^4\text{-Py}$), 7.46 (m, 6H, Ph), 7.15 (ddd, $J = 7.7, 1.8, 1.0$ Hz, 1H, $\text{H}^{3/5}\text{-Py}$), 6.97 (ddd, $J = 7.7, 1.8, 0.9$ Hz, 1H, $\text{H}^{3/5}\text{-Py}$), 4.51 (d, $J = 4.8$ Hz, CH_2OH), 3.84 (d, $J = 11.9$ Hz, CH_2P), 3.21 (t, $J = 4.8$ Hz, CH_2OH) ppm; $^{31}\text{P}\{^1\text{H}\}$ NMR (CDCl_3 , H_3PO_4 ext.): $\delta = 18.78$ (d, $J = 65.6$ Hz, PPh_2BH_3) ppm; IR (KBr): $\bar{\nu} = 2400$ (s) cm^{-1} .

Trihydroborane[6-(*diphenylphosphanyl*- κ *P*-methyl)pyridine-2-carbaldehyde]
(**16**, $\text{C}_{19}\text{H}_{19}\text{BNOP}$)

Procedure as described for **14**, including molar amounts of reactants and quantities of solvent as in the synthesis of **6**. The residue was chromatographed (SiO_2 , $25 \times 3 \text{ cm}$) with petroleum ether:ethyl acetate = 4:1. Compound **16** was obtained as a yellow solid. Yield 0.78 g (79%); mp $65\text{--}66^\circ\text{C}$; PI FD MS (CH_2Cl_2): $m/z = 319$ (M, 100), 305 (M-BH₃, 13); ^1H NMR (400 MHz, CDCl_3 , *TMS*): $\delta = 9.75$ (s, CHO), 7.73 (m, 6H, Ph, Py), 7.45 (m, 7H, Ph, Py), 3.93 (d, $J = 12.0$ Hz, CH_2P) ppm; $^{31}\text{P}\{^1\text{H}\}$ NMR (CDCl_3 , H_3PO_4 ext.): $\delta = 18.97$ (d, $J = 68.7$ Hz, PPh_2BH_3) ppm; IR (KBr): $\bar{\nu} = 2380$ (s), 1710 (s) cm^{-1} .

Trihydroborane[6-(diphenylphosphanyl-κP-methyl)pyridine-2-carbaldoxime]
(**17**, C₁₉H₂₀BN₂OP)

Procedure as described for **14**, including molar amounts of reactants and quantities of solvent as in the synthesis of **7**. The residue was chromatographed (SiO₂, 25×3 cm) with petroleum ether:ethyl acetate = 1:1. Compound **17** was obtained as a colourless solid. Yield 6.22 g (99%); mp 139–140°C; PI FD MS (CH₂Cl₂): *m/z* = 334 (M, 45), 320 (M–BH₃, 100); ¹H NMR (400 MHz, DMSO-d₆, TMS): δ = 11.72 (s, HCNOH), 7.77 (d, *J* = 1.3 Hz, HCNOH), 7.74 (m, 4H, Ph), 7.67 (dd, *J* = 7.7, 7.7 Hz, H⁴-Py), 7.54 (m, 7H, Ph, H⁵-Py), 7.15 (ddd, *J* = 7.7, 1.6, 1.3 Hz, H³-Py), 4.05 (d, *J* = 12.5 Hz, CH₂P) ppm; ³¹P{¹H} NMR (DMSO-d₆, H₃PO₄ ext.): δ = 18.65 (bs, PPh₂BH₃) ppm; IR (KBr): $\bar{\nu}$ = 2380 (s) cm^{–1}.

Trihydroborane[6-(diphenylphosphanyl-κP-methyl)pyridine-2-carbonitrile]
(**18**, C₁₉H₁₈BN₂P)

Procedure as described for **14**, including molar amounts of reactants and quantities of solvent as in the synthesis of **8**. Compound **18** formed a colourless solid. Yield 1.58 g (83%); mp 91°C; PI FD MS (CH₂Cl₂): *m/z* = 316 (M, 100), 302 (M–BH₃, 28); ¹H NMR (400 MHz, CDCl₃, TMS): δ = 7.70 (m, 5H, Ph, Py), 7.57 (ddd, *J* = 8.0, 1.7, 1.1 Hz, H⁵-Py), 7.48 (m, 7H, Ph, Py), 3.88 (d, *J* = 12.1 Hz, CH₂P) ppm; ³¹P{¹H} NMR (CDCl₃, H₃PO₄ ext.): δ = 18.82 (d, *J* = 65.2 Hz, PPh₂BH₃) ppm; IR (KBr): $\bar{\nu}$ = 2400 (s) cm^{–1}.

Trihydroborane[6-(diphenylphosphanyl-κP-methyl)pyridine-2-carbomethoxyimide]
(**19**, C₂₀H₂₂BN₂OP)

Procedure as described for **14**, including molar amounts of reactants and quantities of solvent as in the synthesis of **9**. Compound **19** was obtained as a colourless solid. Purification by chromatography (Al₂O₃, 25×3 cm) with petroleum ether:ethyl acetate = 4:1 decreased the yield. Yield 1.15 g (82%); mp 88–89°C; PI FD MS (CH₂Cl₂): *m/z* = 348 (M, 76), 335 (M–BH₃, 100); ¹H NMR (250 MHz, CDCl₃, TMS): δ = 7.91 (ddd, *J* = 7.8, 1.5, 1.1 Hz, H³-Py), 7.74 (m, 4H, Ph), 7.68 (ddd, *J* = 7.8, 7.8, 0.5 Hz, H⁴-Py), 7.44 (m, 7H, Ph, H⁵-Py), 3.97 (d, *J* = 12.1 Hz, CH₂P), 3.93 (s, OCH₃) ppm; ³¹P{¹H} NMR (CDCl₃, H₃PO₄ ext.): δ = 18.79 (d, *J* = 66.7 Hz, PPh₂BH₃) ppm; IR (KBr): $\bar{\nu}$ = 2390 (s), 1720 (s) cm^{–1}.

General Procedure for the Synthesis of Compounds 20–23 from 19 with 2-Aminoalcohols

To a solution of 800 mg of **19** (2.30 mmol) in 40 cm³ of CH₂Cl₂ a solution of 2.30 mmol of the corresponding 2-aminoalcohol (2.30 mmol) was added under N₂. Stirring was continued for 4 d at room temperature. After removal of the solvent the residue was chromatographed on Al₂O₃ (20×3 cm) with petroleum ether:ethyl acetate = 3:1.

(R)-Trihydroborane[2-(diphenylphosphanyl-κP-methyl)-6-(4-ethyl-4,5-dihydrooxazol-2-yl)pyridine] (**20**, C₂₃H₂₆BN₂OP)

From (R)-(–)-2-aminobutanol as aminoalcohol. Colourless resin. Yield 343 mg (38%); PI FD MS (CH₂Cl₂): *m/z* = 388 (M, 31), 374 (M–BH₃, 100); ¹H{³¹P} NMR (400 MHz, CDCl₃, TMS): δ = 7.83 (dd, *J* = 7.7, 1.0 Hz, H³-Py), 7.73 (m, 4H, Ph), 7.60 (dd, *J* = 7.7, 7.8 Hz, H⁴-Py), 7.44 (m, 7H, Ph, H⁵-Py), 4.50 (dd, *J* = 8.2, 9.4 Hz, OCH^AH^BCHN), 4.27 (m, OCH^AH^BCHN), 4.09 (dd, *J* = 8.2, 8.2 Hz, OCH^AH^BCHN), 4.00 (d, *J* = 14.0 Hz, CH^AH^BPBH₃), 3.93 (d, *J* = 14.0 Hz, CH^AH^BPBH₃), 1.77 (m, CH^AH^BCH₃), 1.63 (m, CH^AH^BCH₃), 0.99 (t, *J* = 7.3 Hz, CH^AH^BCH₃) ppm; ³¹P{¹H} NMR (CDCl₃, H₃PO₄ ext.): δ = 18.56 (d, *J* = 48.8 Hz, PPh₂BH₃) ppm; IR (KBr): $\bar{\nu}$ = 2390 (s) cm^{–1}; [α]_D = +30.0, [α]₅₇₈ = +32.2, [α]₅₄₆ = +37.5, [α]₄₃₆ = +72.7, [α]₃₆₅ = +143.8° cm³ g^{–1} dm^{–1} (*c* = 2.67, CH₂Cl₂).

(*S*)-Trihydroborane[2-(diphenylphosphanyl- κ P-methyl)-6-(4-isopropyl-4,5-dihydrooxazol-2-yl)pyridine] (**21**, C₂₄H₂₈BN₂OP)

From (*S*)-(+)-valinol as aminoalcohol. Colourless resin. Yield 266 mg (30%); PI FD MS (CH₂Cl₂): m/z = 402 (M, 39), 388 (M-BH₃); ¹H{³¹P} NMR (400 MHz, CDCl₃, TMS): δ = 7.85 (dd, J = 7.8, 1.0 Hz, H³-Py), 7.73 (m, 4H, Ph), 7.60 (dd, J = 7.8, 7.8 Hz, H⁴-Py), 7.42 (m, 7H, Ph, H⁵-Py), 4.44 (dd, J = 9.0, 7.6 Hz, OCH^AH^BCHN), 4.15 (m, OCH^AH^BCHN), 4.02 (d, J = 13.9 Hz, CH^AH^BPBH₃), 3.91 (d, J = 13.9 Hz, CH^AH^BPBH₃), 1.89 (m, CHCH₃CH₃), 1.03 (d, J = 6.8 Hz, CHCH₃CH₃), 0.93 (d, J = 6.8 Hz, CHCH₃CH₃) ppm; ³¹P{¹H} NMR (CDCl₃, H₃PO₄ ext.): δ = 18.62 (d, J = 48.8 Hz, PPh₂BH₃) ppm; IR (KBr): $\bar{\nu}$ = 2390 (s) cm⁻¹; [α]_D = -40.5, [α]₅₇₈ = -43.9, [α]₅₄₆ = -50.0, [α]₄₃₆ = -99.3, [α]₃₆₅ = -200.0° cm³ g⁻¹ dm⁻¹ (c = 1.48, CH₂Cl₂).

(*S*)-Trihydroborane[2-(diphenylphosphanyl- κ P-methyl)-6-(4-benzyl-4,5-dihydrooxazol-2-yl)pyridine] (**22**, C₂₈H₂₈BN₂OP)

From (*S*)-(-)-phenylalaninol as aminoalcohol. Colourless resin. Yield 307 mg (30%); PI FD MS (CH₂Cl₂): m/z = 450 (M, 42), 436 (M-BH₃, 100); ¹H{³¹P} NMR (400 MHz, CDCl₃, TMS): δ = 7.84 (dd, J = 7.8, 1.1 Hz, H³-Py), 7.74 (m, 4H, Ph), 7.61 (dd, J = 7.8, 7.8 Hz, H⁴-Py), 7.42 (m, 7H, Ph, H⁵-Py), 7.27 (m, 5H, Ph), 4.61 (m, OCH^ACH^BCHN), 4.38 (dd, J = 8.6, 9.4 Hz, OCH^AH^BCHN), 4.17 (dd, J = 8.6, 7.5 Hz, OCH^AH^BCHN), 4.01 (d, J = 13.8 Hz, CH^AH^BPBH₃), 3.93 (d, J = 13.8 Hz, CH^AH^BPBH₃), 3.26 (dd, J = 13.7, 5.1 Hz, CH^AH^BPBH₃), 2.74 (dd, J = 13.7, 8.9 Hz, CH^AH^BPBH₃) ppm; ³¹P{¹H} NMR (CDCl₃, H₃PO₄ ext.): δ = 18.54 (d, J = 56.5 Hz, PPh₂BH₃) ppm; IR (KBr): $\bar{\nu}$ = 2390 (s) cm⁻¹; [α]_D = -29.9, [α]₅₇₈ = -29.9, [α]₅₄₆ = -34.0, [α]₄₃₆ = -68.7, [α]₃₆₅ = -134.7° cm³ g⁻¹ dm⁻¹ (c = 1.47, CH₂Cl₂).

(*S*)-Trihydroborane[2-(diphenylphosphanyl- κ P-methyl)-6-(4-phenyl-4,5-dihydrooxazol-2-yl)pyridine] (**23**, C₂₇H₂₆BN₂OP)

From (*S*)-(-)-phenylglycinol as aminoalcohol. Colourless resin. Yield 378 mg (38%); PI FD MS (CH₂Cl₂): m/z = 437 (M, 34), 422 (M-BH₃, 100); ¹H{³¹P} NMR (400 MHz, CDCl₃, TMS): δ = 7.96 (dd, J = 7.7, 1.5 Hz, H³-Py), 7.69 (m, 5H, Ph, H⁴-Py), 7.38 (m, 12H, Ph, H⁵-Py), 5.41 (dd, J = 10.1, 8.5 Hz, OCH^AH^BCHN), 5.15 (m, OCH^AH^BCHN), 4.83 (dd, J = 10.1, 8.6 Hz, OCH^AH^BCHN), 4.03 (d, J = 13.8 Hz, CH^AH^BPBH₃), 3.94 (d, J = 13.8 Hz, CH^AH^BPBH₃) ppm; ³¹P{¹H} NMR (CDCl₃, H₃PO₄ ext.): δ = 18.73 (d, J = 47.3 Hz, PPh₂BH₃) ppm; IR (KBr): $\bar{\nu}$ = 2400 (s) cm⁻¹; [α]_D = +60.5, [α]₅₇₈ = +63.8, [α]₅₄₆ = +76.2, [α]₄₃₆ = +155.2, [α]₃₆₅ = +330.5° cm³ g⁻¹ dm⁻¹ (c = 1.05, CH₂Cl₂).

General Procedure for the Synthesis of the Borane-free Compounds **24–27** (and **32**)

In an atmosphere of dry N₂ 0.75 mmol of the borane complex were dissolved in 15 cm³ of Et₂NH and stirred for 5 h at 50°C. After removing the solvent and the volatiles, the residue was dried for 2 h in high vacuum with gentle heating to give the borane-free products **24–27** and **32**.

(*R*)-2-[(Diphenylphosphanyl)methyl]-6-(4-ethyl-4,5-dihydrooxazol-2-yl)pyridine (**24**, C₂₃H₂₃N₂OP)

From **20**. Colourless resin. Yield 261 mg (93%); PI DCI MS: m/z = 391 (M + NH₄, 100), 375 (MH, 8); ¹H{³¹P} NMR (400 MHz, CDCl₃, TMS): δ = 7.84 (dd, J = 7.8, 1.0 Hz, H³-Py), 7.45 (m, 5H, Ph, H⁴-Py), 7.31 (m, 6H, Ph), 6.96 (dd, J = 7.8, 1.0 Hz, H⁵-Py), 4.55 (dd, J = 8.2, 9.5 Hz, OCH^AH^BCHN), 4.28 (m, OCH^AH^BCHN), 4.13 (dd, J = 8.2, 8.2 Hz, OCH^AH^BCHN), 3.76 (d, J = 13.5 Hz, CH^AH^BPPh₂), 3.72 (d, J = 13.5 Hz, CH^AH^BPPh₂), 1.81 (m, CH^AH^BCH₃), 1.63 (m, CH^AH^BCH₃), 1.01 (t, J = 7.4 Hz,

$\text{CH}^{\text{A}}\text{H}^{\text{B}}\text{CH}_3$) ppm; $^{31}\text{P}\{^1\text{H}\}$ NMR (CDCl_3 , H_3PO_4 ext.): $\delta = -10.17$ (s, PPh_2) ppm; $[\alpha]_{\text{D}} = +15.0$, $[\alpha]_{578} = +19.4$, $[\alpha]_{546} = +21.9$, $[\alpha]_{436} = +26.9^\circ \text{cm}^3 \text{g}^{-1} \text{dm}^{-1}$ ($c = 2.12$, CH_2Cl_2).

(S)-2-[(Diphenylphosphanyl)methyl]-6-(4-isopropyl-4,5-dihydrooxazol-2-yl)pyridine
(**25**, $\text{C}_{24}\text{H}_{25}\text{N}_2\text{OP}$)

From **21**. Colourless resin. Yield 270 mg (93%); PI FD MS (CH_2Cl_2): $m/z = 388$ (M, 100); $^1\text{H}\{^{31}\text{P}\}$ NMR (400 MHz, CDCl_3 , TMS): $\delta = 7.86$ (ddd, $J = 7.8, 1.1, 1.1$ Hz, $\text{H}^3\text{-Py}$), 7.50 (ddd, $J = 7.8, 7.8, 0.3$ Hz, $\text{H}^4\text{-Py}$), 7.44 (m, 4H, Ph), 7.31 (m, 6H, Ph), 6.97 (ddd, $J = 7.8, 1.1, 1.2$ Hz, $\text{H}^5\text{-Py}$), 4.49 (dd, $J = 8.2, 9.5$ Hz, $\text{OCH}^{\text{A}}\text{H}^{\text{B}}\text{CHN}$), 4.22 (dd, $J = 8.2, 8.3$ Hz, $\text{OCH}^{\text{A}}\text{H}^{\text{B}}\text{CHN}$), 4.14 (m, $\text{OCH}^{\text{A}}\text{H}^{\text{B}}\text{CHN}$), 3.76 (d, $J = 13.3$ Hz, $\text{CH}^{\text{A}}\text{H}^{\text{B}}\text{PPh}_2$), 3.71 (d, $J = 13.3$ Hz, $\text{CH}^{\text{A}}\text{H}^{\text{B}}\text{PPh}_2$), 1.90 (m, CHCH_3CH_3), 1.05 (d, $J = 6.8$ Hz, CHCH_3CH_3), 0.94 (d, $J = 6.8$ Hz, CHCH_3CH_3) ppm; $^{31}\text{P}\{^1\text{H}\}$ NMR (CDCl_3 , H_3PO_4 ext.): $\delta = -10.10$ (s, PPh_2) ppm; $[\alpha]_{\text{D}} = -16.6$, $[\alpha]_{578} = -17.9$, $[\alpha]_{546} = -21.2$, $[\alpha]_{436} = -41.3^\circ \text{cm}^3 \text{g}^{-1} \text{dm}^{-1}$ ($c = 3.92$, CH_2Cl_2).

(S)-2-[(Diphenylphosphanyl)methyl]-6-(4-benzyl-4,5-dihydrooxazol-2-yl)pyridine
(**26**, $\text{C}_{28}\text{H}_{25}\text{N}_2\text{OP}$)

From **22**. Colourless resin. Yield 288 mg (88%); PI FD MS (CH_2Cl_2): $m/z = 436$ (M, 100); $^1\text{H}\{^{31}\text{P}\}$ NMR (400 MHz, CDCl_3 , TMS): $\delta = 7.84$ (ddd, $J = 7.8, 1.2, 1.1$ Hz, $\text{H}^3\text{-Py}$), 7.52 (ddd, $J = 7.8, 7.8, 0.3$ Hz, $\text{H}^4\text{-Py}$), 7.44 (m, 4H, Ph), 7.31 (m, 8H, Ph), 7.25 (m, 3H, Ph), 6.98 (ddd, $J = 7.8, 1.2, 1.2$ Hz, $\text{H}^5\text{-Py}$), 4.63 (m, $\text{OCH}^{\text{A}}\text{H}^{\text{B}}\text{CHN}$), 4.43 (dd, $J = 8.6, 9.4$ Hz, $\text{OCH}^{\text{A}}\text{H}^{\text{B}}\text{CHN}$), 4.23 (dd, $J = 8.6, 7.6$ Hz, $\text{OCH}^{\text{A}}\text{H}^{\text{B}}\text{CHN}$), 3.76 (d, $J = 13.4$ Hz, $\text{CH}^{\text{A}}\text{H}^{\text{B}}\text{PPh}_2$), 3.72 (d, $J = 13.4$ Hz, $\text{CH}^{\text{A}}\text{H}^{\text{B}}\text{PPh}_2$), 3.30 (dd, $J = 13.7, 4.8$ Hz, $\text{CH}^{\text{A}}\text{H}^{\text{B}}\text{Ph}$), 2.75 (dd, $J = 13.7, 9.3$ Hz, $\text{CH}^{\text{A}}\text{H}^{\text{B}}\text{Ph}$) ppm; $^{31}\text{P}\{^1\text{H}\}$ NMR (CDCl_3 , H_3PO_4 ext.): $\delta = -10.06$ (s, PPh_2) ppm; $[\alpha]_{\text{D}} = -15.3$, $[\alpha]_{578} = -17.4$, $[\alpha]_{546} = -20.4$, $[\alpha]_{436} = -47.0^\circ \text{cm}^3 \text{g}^{-1} \text{dm}^{-1}$ ($c = 0.98$, CH_2Cl_2).

(S)-2-[(Diphenylphosphanyl)methyl]-6-(4-phenyl-4,5-dihydrooxazol-2-yl)pyridine
(**27**, $\text{C}_{27}\text{H}_{23}\text{N}_2\text{OP}$)

From **23**. Colourless resin. Yield 285 mg (90%); PI DCI MS: $m/z = 423$ (MH, 100), 239 (MH- PPh_2 , 50); $^1\text{H}\{^{31}\text{P}\}$ NMR (400 MHz, CDCl_3 , TMS): $\delta = 7.94$ (ddd, $J = 7.8, 2.1, 1.1$ Hz, $\text{H}^3\text{-Py}$), 7.53 (dd, $J = 7.8, 7.8$ Hz, $\text{H}^4\text{-Py}$), 7.36 (m, 15H, Ph), 7.01 (ddd, $J = 7.8, 1.1, 1.2$ Hz, $\text{H}^5\text{-Py}$), 5.42 (dd, $J = 8.5, 10.3$ Hz, $\text{OCH}^{\text{A}}\text{H}^{\text{B}}\text{CHN}$), 4.88 (dd, $J = 8.5, 10.3$ Hz, $\text{OCH}^{\text{A}}\text{H}^{\text{B}}\text{CHN}$), 4.37 (dd, $J = 8.5, 8.5$ Hz, $\text{OCH}^{\text{A}}\text{H}^{\text{B}}\text{CHN}$), 3.78 (d, $J = 13.2$ Hz, $\text{CH}^{\text{A}}\text{H}^{\text{B}}\text{PPh}_2$), 3.74 (d, $J = 13.2$ Hz, $\text{CH}^{\text{A}}\text{H}^{\text{B}}\text{PPh}_2$) ppm; $^{31}\text{P}\{^1\text{H}\}$ NMR (CDCl_3 , H_3PO_4 ext.): $\delta = -9.83$ (s, PPh_2) ppm; $[\alpha]_{\text{D}} = +15.5$, $[\alpha]_{578} = +16.9$, $[\alpha]_{546} = +21.0$, $[\alpha]_{436} = +43.9^\circ \text{cm}^3 \text{g}^{-1} \text{dm}^{-1}$ ($c = 1.48$, CH_2Cl_2).

Trihydroborane[(S)-N-Boc-4-(diphenylphosphanyl-κP-methyl)-2,2-dimethyloxazolidine]
(**29**, $\text{C}_{23}\text{H}_{33}\text{BNO}_3\text{P}$)

(S)-N-Boc-2,2-dimethyl-4-(tosyloxymethyl)oxazolidine (**28**, 1.50 g, 3.89 mmol) was dissolved in 50 cm^3 of THF under N_2 . An equimolar amount of LiPPh_2 in THF was added dropwise at 0°C . After stirring for 3 h at 0°C 3.89 cm^3 of a solution of $\text{BH}_3\cdot\text{THF}$ (3.89 mmol) were added and the solution was stirred for 3 h at room temperature. The solvent was removed and the residue was chromatographed (SiO_2 , 25×3 cm) with petroleum ether:ethyl acetate = 6:1. **29** was obtained as a colourless solid. Yield 1.10 g (68%); mp $82\text{--}83^\circ\text{C}$; PI FD MS (CH_2Cl_2): $m/z = 413$ (M, 7), 399 (M- BH_3 , 100); ^1H NMR (250 MHz, CDCl_3 , TMS): Two isomers, ratio 1:1.4; signals of the minor isomer in brackets: $\delta = 7.70$ (m, 10H, Ph), 4.29 [3.85] (m, $\text{CH}^{\text{A}}\text{H}^{\text{B}}\text{O}$), 4.09 [3.66] (m, CHNBoc), 4.15 [3.78] (m, $\text{CH}^{\text{A}}\text{H}^{\text{B}}\text{O}$), 3.09 [2.59] (m, $\text{CH}^{\text{A}}\text{H}^{\text{B}}\text{P}$), 2.59 [2.29] (m, $\text{CH}^{\text{A}}\text{H}^{\text{B}}\text{P}$), 1.51 (m, $\text{C}(\text{CH}_3)_2$) ppm; $^{31}\text{P}\{^1\text{H}\}$ NMR (CDCl_3 , H_3PO_4 ext.): $\delta = 11.74$ (m, PPh_2BH_3) ppm; IR (KBr): $\bar{\nu} = 2380$ (s) cm^{-1} .

Trihydroborane[(S)-2-amino-3-diphenylphosphanyl-κP-propanol]hydrochloride
(**30**, C₁₅H₂₁BNOP·HCl)

Under N₂ 200 mg of **29** (0.4 mmol) were dissolved in 5 cm³ of MeOH. To this solution 5 cm³ of a methanol solution saturated with HCl were added at 0°C. With a reaction time of 5 min it is possible to cleave the oxazolidine ring without destroying the phosphorus-borane complex. **30** was formed as the hydrochloride. Yield 124 mg (100%); PI DCI MS: m/z = 274 (MH, 4), 260 (M–BH₃, 100), 187 (Ph₂PH, 35); ¹H NMR (250 MHz, CDCl₃, TMS): δ = 8.15 (bs, CHNH₃Cl), 7.70 (m, 4H, H²-Ph), 7.40 (m, 6H, H³-Ph, H⁴-Ph), 3.63 (m, HOCH₂CHNH₂), 2.86 (m, CH₂P) ppm; ³¹P{¹H} NMR (CDCl₃, H₃PO₄ ext.): δ = 12.43 (s, PPh₂BH₃) ppm; IR (KBr): $\bar{\nu}$ = 2390 (s) cm^{–1}.

Trihydroborane[(S)-2-[4-(diphenylphosphanyl-κP-methyl)-4,5-dihydrooxazol-2-yl]pyridine] (**31**, C₂₁H₂₂BN₂OP)

Pyridine-2-carbomethoxyimide (375 mg, 1.21 mmol) was dissolved in 20 cm³ of CH₂Cl₂ and 151 mm³ of **30** (1.21 mmol) were added. After addition of 171 mm³ of NEt₃ (2.3 mmol) to deprotect the amino function of **30**, the solution was stirred for 4 d at room temperature. The solvent was removed and the residue was chromatographed (Al₂O₃, 20 × 1.5 cm) with petroleum ether:ethyl acetate = 3:1. **31** was isolated as a colourless resin. Yield 388 mg (40%); PI FD MS (CH₂Cl₂): m/z = 360 (M, 89), 346 (M–BH₃, 100); ¹H{³¹P} NMR (400 MHz, CDCl₃, TMS): δ = 8.70 (ddd, J = 4.8, 1.8, 0.9 Hz, H⁶-Py), 7.90 (ddd, J = 7.9, 1.1, 0.9 Hz, H³-Py), 7.80 (m, 2H, Ph), 7.76 (ddd, J = 7.6, 7.9, 1.8 Hz, H⁴-Py), 7.68 (m, 2H, Ph), 7.47 (m, 6H, Ph), 7.39 (ddd, J = 4.8, 7.6, 1.1 Hz, H⁵-Py), 4.59 (dd, J = 8.7, 17.7 Hz, OCH^AH^BCHN), 4.52 (m, OCH^AH^BCHN), 4.28 (dd, J = 8.7, 7.1 Hz, OCH^AH^BCHN), 3.16 (dd, J = 14.4, 2.5 Hz, CH^AH^BP), 2.35 (dd, J = 14.4, 10.6 Hz, CH^AH^BP) ppm; ³¹P{¹H} NMR (CDCl₃, H₃PO₄ ext.): δ = 12.28 (d, J = 62.6 Hz, PPh₂BH₃) ppm; IR (KBr): $\bar{\nu}$ = 2380 (s) cm^{–1}; [α]_D = +32.0, [α]₅₇₈ = +32.8, [α]₅₄₆ = +40.0, [α]₄₃₆ = +84.4, [α]₃₆₅ = +180.0° cm³ g^{–1} dm^{–1} (c = 1.25, CH₂Cl₂).

(S)-2-[4-[(Diphenylphosphanyl)methyl]-4,5-dihydrooxazol-2-yl]pyridine
(**32**, C₂₁H₁₉N₂OP)

From **31** according to the general procedure for removal of the BH₃ protecting group. Colourless resin. Yield 235 mg (90%); PI FD MS (CH₂Cl₂): m/z = 346 (M, 100); ¹H{³¹P} NMR (400 MHz, CDCl₃, TMS): δ = 8.69 (ddd, J = 4.8, 1.8, 0.9 Hz, H⁶-Py), 7.96 (ddd, J = 7.9, 1.1, 0.9 Hz, H³-Py), 7.74 (ddd, J = 7.9, 7.6, 1.8 Hz, H⁴-Py), 7.51 (m, 2H, Ph), 7.43 (m, 2H, Ph), 7.37 (ddd, J = 4.8, 7.6, 1.8 Hz, H⁵-Py), 7.33 (m, 6H, Ph), 4.53 (dd, J = 8.4, 9.1 Hz, OCH^AH^BCHN), 4.37 (m, OCH^AH^BCHN), 4.26 (dd, J = 8.4, 7.9 Hz, OCH^AH^BCHN), 2.86 (ddd, J = 13.5, 4.1, 1.9 Hz, CH^AH^BPPh₂), 2.22 (ddd, J = 13.5, 10.2, 2.7 Hz, CH^AH^BPPh₂) ppm; ³¹P{¹H} NMR (CDCl₃, H₃PO₄ ext.): δ = –22.03 (s, PPh₂) ppm; [α]_D = +16.9, [α]₅₇₈ = +18.8, [α]₅₄₆ = +21.1, [α]₄₃₆ = +37.0° cm³ g^{–1} dm^{–1} (c = 3.84, CH₂Cl₂).

(S)-2-[4-[2-(Methylthio)ethyl]-4,5-dihydrooxazol-2-yl]pyridine
(**33**, C₁₁H₁₄H₂OS)

[α]_D = –88.2, [α]₅₇₈ = –94.1, [α]₅₄₆ = –107.8, [α]₄₃₆ = –201.0, [α]₃₆₅ = –371.6° cm³ g^{–1} dm^{–1} (c = 1.02, CH₂Cl₂).

(S)-2-[4-[2-(Methylthio)ethyl]-4,5-dihydrooxazol-2-yl]pyridine·CuCl₂
(**34**, C₁₁H₁₄Cl₂CuN₂OS)

To a solution of 87.4 mg of **33** (0.39 mmol) in 15 cm³ of MeOH, a solution of 67.0 mg of CuCl₂·2H₂O (0.40 mmol) in 5 cm³ of MeOH was added. The colour changed immediately to blue/turquoise. After stirring for 2 h at room temperature the solvent was removed. The residue was dissolved in a small

amount of *MeOH* and ether was added. After a few days at -30°C green crystals were obtained, which were suitable for X-ray structure analysis. Yield 110 mg (77%); LT PI LSI MS: $m/z = 385$ ($M + \text{MeOH}$, 16), 320 ($M - \text{Cl}$, 73), 285 ($M - 2\text{Cl}$, 100).

X-Ray Structure Analysis of **14** and **34**

Data were collected with an imaging plate diffraction system (Stoe-IPDS, Stoe & CIE GmbH, Darmstadt, Germany), using $\text{Mo-K}\alpha$ radiation, $\lambda = 0.71073 \text{ \AA}$, with a graphite monochromator. Numerical absorption correction was applied for compound **34**. For data reduction the Stoe-IPDS software (Stoe 1998) was used [28]. The structure was solved with direct methods (SIR-97) [29] and refined by full-matrix least-squares techniques (SHELXL 97) [30]. All H atoms were included at calculated positions and refined using a riding model.

These data can be obtained free of charge at www.ccdc.cam.ac.uk/conts/retrieving.html or from the Cambridge Crystallographic Data Centre, 12 Union Road, Cambridge CB2 1EZ, UK [Fax: (internat.) +44-1223/336-033, E-mail: deposit@ccdc.cam.ac.uk].

Crystal data of 14. $\text{C}_{35}\text{H}_{39}\text{BNOPSi}$, $M = 559.54$, $T = 173(1) \text{ K}$, translucent colourless prism, monoclinic, $P2_1/a$, $a = 14.8737(9)$, $b = 12.4055(6)$, $c = 18.1180(12) \text{ \AA}$, $\beta = 112.640(7)^{\circ}$, $V = 3085.4(4) \text{ \AA}^3$, $Z = 4$, $\mu = 0.156 \text{ mm}^{-1}$, reflections collected = 27171, independent = 5009, final R indices [$I > 2\sigma_I$]: $R_1 = 0.0412$, $wR_2 = 0.1101$. CCDC 199583.

Crystal data of 34. $\text{C}_{11}\text{H}_{14}\text{Cl}_2\text{CuN}_2\text{OS}$, $M = 356.76$, $T = 173(1) \text{ K}$, translucent blue-green rod, orthorhombic, $P2_12_12_1$, $a = 8.3529(6)$, $b = 10.7267(7)$, $c = 16.0409(13) \text{ \AA}$, $V = 1437.25(18) \text{ \AA}^3$, $Z = 4$, $\mu = 2.025 \text{ mm}^{-1}$, reflections collected = 18994, independent = 2741, final R indices [$I > 2\sigma_I$]: $R_1 = 0.0207$, $wR_2 = 0.0488$. CCDC 199582.

References

- [1] Part 148: Brunner H, Schönherr M, Zabel M (2003) *Tetrahedron: Asymmetry* **14**: 1115
- [2] Brunner H, Zettlmeier W (1993) *Handbook of Enantioselective Catalysis with Transition Metal Compounds*, VCH, Weinheim
- [3] Zettler C (2002) Dissertation, University of Regensburg
- [4] Kocienski PJ (1994) *Protecting Groups*, Thieme, New York, p 38
- [5] Horvath G, Russa C, Koentoes Z, Gerencser J (1999) *Synth Commun* 3719
- [6] Yadav JS, Maiti A (2002) *Tetrahedron* **58**: 4955
- [7] Martin SF, Chen H, Yang CP (1993) *J Org Chem* **58**: 2873
- [8] Becker HGO (1999) *Organikum*, Wiley-VCH, Weinheim, p 398
- [9] Kim BH, Jeong EJ, Hwang GT, Venkatesan N (2001) *Synthesis* 2191
- [10] Chelucci G, Cabras MA, Botteghi C, Basoli C, Marchetti M (1996) *Tetrahedron: Asymmetry* **7**: 885
- [11] Schaefer FC, Peters GA (1961) *J Org Chem* **26**: 412
- [12] Meyers AI, Knaus G, Kamata K (1974) *J Am Chem Soc* **96**: 268
- [13] Horner L, Balzer WD (1965) *Tetrahedron Lett* 1157
- [14] Naumann K, Zon G, Mislow G (1969) *J Am Chem Soc* **91**: 7012
- [15] Pellon P (1992) *Tetrahedron Lett* **31**: 4451
- [16] Börner A, Ward J, Ruth W, Holz J, Kless A, Heller D, Kagan HB (1994) *Tetrahedron* **50**: 10419
- [17] Imamoto T, Oshiki T, Onozawa T, Kusumoto T, Sato K (1990) *J Am Chem Soc* **112**: 5244
- [18] McKillop A, Taylor RJK, Watson RJ, Lewis N (1994) *Synthesis* 31
- [19] Garner P, Park JM (1987) *J Org Chem* **52**: 2361
- [20] Porte AM, Reitenspies J, Burgess K (1998) *J Am Chem Soc* **120**: 9180
- [21] Schürch M, Schwalm O, Mallat T, Weber J, Baiker A (1997) *J Catal* **169**: 275
- [22] Tracht T (1998) *Tetrahedron: Asymmetry* **9**: 3763

- [23] Brunner H, Riepl G, Weitzer H (1983) *Angew Chem Int Ed Engl* **22**: 331
- [24] Brunner H, Obermann U (1989) *Chem Ber* **122**: 499
- [25] Noyori R, Hashiguchi S (1997) *Acc Chem Res* **30**: 97
- [26] Brunner H, Henning F, Weber M (2002) *Tetrahedron: Asymmetry* **13**: 37
- [27] Itsuno S, Hirao A, Nakahama S, Yamazaki N (1983) *J Chem Soc, Perkin Trans 1*: 1673
- [28] STOE IPDS-software (1998) version 2.89, STOE & Cie GmbH, Darmstadt, Germany
- [29] Altomare A, Cascarano G, Giacovazzo C, Guagliardi A (1993) *J Appl Crystallogr* **26**: 343
- [30] Sheldrick GM (1997) SHELXL97, Program for Crystal Structure Refinement, University of Göttingen, Göttingen, Germany